Biosimilars example sentences

"Biosimilars" Example Sentences

1. The FDA recently approved several new biosimilars for the treatment of rheumatoid arthritis.
2. Biosimilars offer a potentially cost-effective alternative to originator biologics.
3. Concerns remain regarding the interchangeability of some biosimilars.
4. The market for biosimilars is expected to grow significantly in the coming years.
5. Many patients are unaware of the availability of biosimilars.
6. Research into the efficacy and safety of biosimilars is ongoing.
7. Physicians need more education about the appropriate use of biosimilars.
8. Cost savings associated with biosimilars can be substantial.
9. Regulatory pathways for approving biosimilars vary internationally.
10. Patent expirations are driving the development of more biosimilars.
11. Increased competition from biosimilars may lower drug prices.
12. Biosimilars are not identical copies of originator biologics.
13. The use of biosimilars is expanding rapidly in Europe.
14. Switching patients from originator biologics to biosimilars requires careful monitoring.
15. Understanding the subtle differences between biosimilars is crucial.
16. Are biosimilars as effective as their reference products? That's a key question.
17. Patient acceptance of biosimilars is a factor influencing market penetration.
18. What are the long-term safety implications of using biosimilars?
19. The development of biosimilars requires extensive preclinical and clinical testing.
20. Pharmaceutical companies are investing heavily in the development of biosimilars.
21. Biosimilars represent a significant advancement in biopharmaceutical technology.
22. Policy makers are debating the best strategies to promote the use of biosimilars.
23. Despite their benefits, biosimilars face considerable challenges to market entry.
24. Public health initiatives are encouraging the use of biosimilars to control healthcare costs.
25. Many questions remain unanswered regarding the long-term effects of biosimilars.
26. Improved access to biosimilars could improve patient outcomes.
27. The future of biosimilars looks promising.
28. Biosimilars, a complex topic, requires careful consideration.
29. Further research is needed to clarify the efficacy of biosimilars in different populations.
30. Successfully launching biosimilars requires a robust marketing strategy.
31. Regulatory hurdles surrounding biosimilars are significant.
32. Despite the cost savings, biosimilars also pose unique logistical challenges.
33. Education is key to increasing the acceptance of biosimilars amongst healthcare providers.
34. The interchangeability of biosimilars is a subject of ongoing debate.
35. Several factors influence the pricing of biosimilars in the marketplace.
36. Transparency is important when discussing the potential benefits and risks of biosimilars.
37. With increasing availability, biosimilars are transforming the landscape of biopharmaceutical treatments.
38. Competition amongst biosimilars manufacturers is fierce.
39. The clinical trials demonstrating the efficacy of biosimilars are rigorously evaluated.
40. Biosimilars offer a pathway to more affordable healthcare.
41. Understanding the similarities and differences between originator biologics and biosimilars is paramount.
42. The successful adoption of biosimilars depends on several interacting factors.
43. Improved communication is essential for fostering trust in biosimilars.
44. Ongoing monitoring of patients receiving biosimilars is crucial for safety surveillance.
45. Addressing patient concerns about the safety of biosimilars is a priority.
46. The economic impact of biosimilars on healthcare systems is substantial.
47. Pharmacovigilance systems play a key role in monitoring the safety of biosimilars post-market.
48. Healthcare providers need to be well-informed about the benefits and risks of biosimilars to make sound clinical decisions.
49. Global health organizations are actively promoting the adoption of biosimilars in developing countries.
50. Access to affordable biosimilars can significantly improve global health equity.